Skip to main content

Table 10 Associations between GLO1 genotype and breast cancer according to menopausal status and tumor stage

From: CYP17, GSTP1, PON1 and GLO1gene polymorphisms as risk factors for breast cancer: an Italian case-control study

  AA AE EE AE and EE
Premenopausal     
   Controls, n (%) 104 (45.2) 88 (38.3) 38 (16.5) 126 (54.8)
   Cases by stage     
Local, n (%) 26 (23.6) 50 (45.4) 34 (31.0) 84 (76.4)
OR (95% CI)a 1.0 2.17 (1.16–4.0) 3.58 (1.82–7.08)b 2.66 (1.58–4.57)
Advanced, n (%) 13 (16.9) 34 (44.1) 30 (39.0) 64 (83.1)
OR (95% CI)a 1.0 3.05 (1.35–6.65) 6.29 (2.78–14.34)c 4.08 (2.02–4.20)
Postmenopausal     
   Controls, n (%) 213 (67.8) 71 (22.6) 30 (9.6) 101 (32.2)
   Cases by stage     
Local, n (%) 55 (24.1) 98 (43.0) 75 (32.9) 173 (75.9)
OR (95% CI)a 1.0 5.31 (3.39–8.25) 9.64 (5.59–16.82)d 6.63 (4.43–9.95)
Advanced, n (%) 25 (19.0) 79 (59.8) 28 (21.2) 107 (81.0)
OR (95% CI)a 1.0 9.44 (5.40–16.55) 7.99 (3.95–16.30)e 8.66 (4.89–15.20)
  1. aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. b, c, d, eP for trend = 0.001.